In a report released yesterday, Kaveri Pohlman from BTIG maintained a Buy rating on G1 Therapeutics (GTHX – Research Report), with a price target of $51.00. The company’s shares closed last Wednesday at $7.82, close to its 52-week low of $7.28.
According to TipRanks.com, Pohlman ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -29.0% and a 18.4% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Checkmate Pharmaceuticals, and Oncternal Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for G1 Therapeutics with a $46.50 average price target.
Based on G1 Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.8 million and GAAP net loss of $40.02 million. In comparison, last year the company earned revenue of $16.55 million and had a GAAP net loss of $25.35 million.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GTHX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Read More on GTHX:
- Aerovate Therapeutics (AVTE) Gets a Buy Rating from BTIG
- PPL (PPL) Gets a Hold Rating from Mizuho Securities
- Fulcrum Therapeutics (FULC) Gets a Buy Rating from Leerink Partners
- Zurn Water Solutions (ZWS) Gets a Buy Rating from Oppenheimer
- Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from JMP Securities